The study authors cited concerns about the veracity of data used in their analysis. The study, published last month, led the WHO to halt enrollment into the hydroxychloroquine arm of a clinical trial, while the French government revoked its authorization of the drug.
A randomized, placebo-controlled trial published in NEJM found the malaria drug was not effective as a post-exposure prophylaxis against coronavirus disease. However, questions have arisen about data used in a large observational study about the drug published last month.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It’s no mystery why obesity rates are high in the U.S. with our plentiful array of fast food options and unlimited access to sugary sodas. But now other areas of the world are getting their junk food fix, which will affect rates in countries that traditionally have healthy, well-rounded diets. New studies, published last week […]